NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRXP NRX Pharmaceuticals Inc.

Closed 04-09 16:00:00 EDT

2.26

+0.01

+0.44%

盘后2.34

+0.08+3.54%

19:56 EDT

High2.29	Low2.21	Vol393.64K
Open2.25	D1 Closing2.25	Amplitude3.56%
Mkt Cap74.73M	Tradable Cap54.87M	Total Shares33.07M
T/O888.53K	T/O Rate1.62%	Tradable Shares24.28M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRXP","market":"US","secType":"STK","nameCN":"NRX Pharmaceuticals Inc.","latestPrice":2.26,"timestamp":1775764800000,"preClose":2.25,"halted":0,"volume":393638,"hourTrading":{"tag":"盘后","latestPrice":2.34,"preClose":2.26,"latestTime":"19:56 EDT","volume":12846,"amount":29251.553,"timestamp":1775778968815,"change":0.08,"changeRate":0.035398,"amplitude":0.035398},"delay":0,"changeRate":0.00444444444444435,"floatShares":24277600,"shares":33067630,"eps":-1.339999,"marketStatus":"Closed","change":0.01,"latestTime":"04-09 16:00:00 EDT","open":2.25,"high":2.29,"low":2.21,"amount":888532.1719246,"amplitude":0.035556,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.339999,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775808000000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":2.25,"preHourTrading":{"tag":"盘前","latestPrice":2.3,"preClose":2.25,"latestTime":"07:05 EDT","volume":1253,"amount":2872.0699644,"timestamp":1775732720933,"change":0.05,"changeRate":0.022222,"amplitude":0.026667},"postHourTrading":{"tag":"盘后","latestPrice":2.34,"preClose":2.26,"latestTime":"19:56 EDT","volume":12846,"amount":29251.553,"timestamp":1775778968815,"change":0.08,"changeRate":0.035398,"amplitude":0.035398},"volumeRatio":0.685843,"impliedVol":0.6016,"impliedVolPercentile":0.104},"requestUrl":"/m/hq/s/NRXP/tweets","defaultTab":"tweets","newsList":[{"id":"2625167634","title":"NRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Labeling Alignment for NRx’s Preservative-Free Ketamine Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2625167634","media":"GlobeNewswire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625167634?lang=en_us&edition=fundamental","pubTime":"2026-04-06 19:00","pubTimestamp":1775473200,"startTime":"0","endTime":"0","summary":"NRx has received a letter from the FDA Office of Generic Drugs indicating preliminary alignment on labeling for NRx’s preservative-free ketamine product. Labeling remains subject to final supervisory ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/06/3268338/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Announces-FDA-Labeling-Alignment-for-NRx-s-Preservative-Free-Ketamine-Application.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","LABU","BK4588","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623140311","title":"NRx unit Hope Therapeutics partners with Emobot to deploy AI depression monitoring networkwide","url":"https://stock-news.laohu8.com/highlight/detail?id=2623140311","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623140311?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:07","pubTimestamp":1774868867,"startTime":"0","endTime":"0","summary":"Hope Therapeutics, NRx Pharmaceuticals subsidiary, formed strategic partnership with Emobot to deploy AI “Depression Thermometer” across its interventional psychiatry clinic network.Rollout targets relapse detection in treatment-resistant depression, where about 50% of patients relapse within 6–12 months between visits.Emobot platform validation across three prospective studies showed concordance with MADRS  and PHQ-9 .Hope expects integration to support earlier “recapture” interventions such as maintenance ketamine or TMS sessions, aiming to double patient success rates.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL89G8n0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4007","SG9999014013.SGD","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4588","LU2210149790.SGD","LU2095319765.USD","NRXP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623311325","title":"Hope Therapeutics, an NRX Pharmaceuticals Subsidiary (Nasdaq:Nrxp), Announces Strategic Partnership With Emobot to Integrate Its AI-Powered “Depression Thermometer” Across Its Interventional Psychiatry Network","url":"https://stock-news.laohu8.com/highlight/detail?id=2623311325","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623311325?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:00","pubTimestamp":1774868403,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nTUA5XLGLM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622022585","title":"Analysts Are Bullish on Top Healthcare Stocks: NRX Pharmaceuticals (NRXP), Rezolute (RZLT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2622022585","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622022585?lang=en_us&edition=fundamental","pubTime":"2026-03-25 18:11","pubTimestamp":1774433472,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on NRX Pharmaceuticals (NRXP), Rezolute (RZLT) and Spec...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-nrx-pharmaceuticals-nrxp-rezolute-rzlt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-top-healthcare-stocks-nrx-pharmaceuticals-nrxp-rezolute-rzlt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RZLT","LABU","BK4007","BK4137","LU0029874061.USD","XBI","BK4581","BLSX","NRXP","BLSG","BK4112","LU0128526141.USD","BK4588","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622042633","title":"Nrx Pharmaceuticals: Extensive Clinical, Regulatory, and Financial Risks Make Shares Highly Speculative","url":"https://stock-news.laohu8.com/highlight/detail?id=2622042633","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622042633?lang=en_us&edition=fundamental","pubTime":"2026-03-25 14:00","pubTimestamp":1774418421,"startTime":"0","endTime":"0","summary":"Nrx Pharmaceuticals, Inc. (NRXP) has disclosed a new risk, in the Accounting & Financial Operations category. Nrx Pharmaceuticals, Inc. faces a bro...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nrx-pharmaceuticals-extensive-clinical-regulatory-and-financial-risks-make-shares-highly-speculative?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nrx-pharmaceuticals-extensive-clinical-regulatory-and-financial-risks-make-shares-highly-speculative?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622013438","title":"NRX Pharmaceuticals held annual shareholder meeting, investors approved incentive plan amendment","url":"https://stock-news.laohu8.com/highlight/detail?id=2622013438","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622013438?lang=en_us&edition=fundamental","pubTime":"2026-03-25 04:33","pubTimestamp":1774384388,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals held its 2025 Annual Meeting, at which stockholders approved an amendment to the 2021 Omnibus Incentive Plan.The amendment increased the plan’s annual automatic share increase to the lesser of 3,187,234 shares, 5% of shares outstanding, or a board-determined amount.Stockholders also ratified Weinberg & Company, P.A. as the company’s independent registered public accounting firm.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on March 24, 2026, and is solely responsible for the information contained t","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nNDL5fwRft:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622209196","title":"NRX Pharmaceuticals Price Target Maintained With a $25.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2622209196","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622209196?lang=en_us&edition=fundamental","pubTime":"2026-03-25 00:31","pubTimestamp":1774369860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 24, 2026 12:31 ET (16:31 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621060245","title":"NRX Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2621060245","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621060245?lang=en_us&edition=fundamental","pubTime":"2026-03-24 21:31","pubTimestamp":1774359078,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings SummaryNRX Pharmaceuticals Inc NRXP.OQ reported a quarterly adjusted loss of 1 cent per share for the quarter ended","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL8N40C1JP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621015066","title":"NRx Pharmaceuticals (Nasdaq:NRXP) Reports Full-Year 2025 Results and Highlights Key Regulatory and Commercial Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2621015066","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621015066?lang=en_us&edition=fundamental","pubTime":"2026-03-24 19:00","pubTimestamp":1774350000,"startTime":"0","endTime":"0","summary":"Key highlights for the first full year of operation under the new management team include: A year-over-year reduction in operating expenses with $7.8 Million cash on hand at year end. With ongoing rev","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/24/3261064/0/en/NRx-Pharmaceuticals-Nasdaq-NRXP-Reports-Full-Year-2025-Results-and-Highlights-Key-Regulatory-and-Commercial-Progress.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","LU2065732104.USD","HOPE","BK4211","BK4588","BK4007","LABU","BK4097","BK4585","PRGS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621080577","title":"NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000K","url":"https://stock-news.laohu8.com/highlight/detail?id=2621080577","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621080577?lang=en_us&edition=fundamental","pubTime":"2026-03-24 06:08","pubTimestamp":1774303683,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals (NASDAQ:NRXP) reported quarterly earnings of $0.20 per share. This is a 125.97 percent increase over losses of $(0.77) per share from the same period last year.  The company reported $983.000 thousand","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/03/51421788/nrx-pharmaceuticals-q4-eps-0-20-up-from-0-77-yoy-sales-983-000k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"NRX Pharmaceuticals Q4 EPS $0.20 Up From $(0.77) YoY, Sales $983.000K","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621844320","title":"NRx Pharmaceuticals FY 2025 net loss was USD 29 million as interest expense rose 192% to USD 1 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2621844320","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621844320?lang=en_us&edition=fundamental","pubTime":"2026-03-24 04:32","pubTimestamp":1774297934,"startTime":"0","endTime":"0","summary":"NRx Pharma published its annual report on Form 10-K for the year ended Dec. 31, 2025, reporting a net loss of USD 28.6 million.Net patient service revenue was USD 1.2 million, reflecting patient services provided by Dura following its acquisition on Sept. 8, 2025.Research and development expense fell 39.07% to USD 3.8 million, driven mainly by lower clinical trials and development spending and reduced regulatory and process development consulting costs.Cash was USD 7.8 million at Dec. 31, 2025, while net cash used in operating activities rose 32.66% to USD 14.1 million.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NRX Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data G","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260323:nNDL6r5ppt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620739499","title":"NRX Pharmaceuticals Inc  expected to post breakeven results a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2620739499","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620739499?lang=en_us&edition=fundamental","pubTime":"2026-03-20 21:16","pubTimestamp":1774012566,"startTime":"0","endTime":"0","summary":"NRX Pharmaceuticals Inc  expected to post breakeven results a share - Earnings Preview NRX Pharmaceuticals Inc NRXP.OQ NRXP.O is expected to  show a rise in quarterly revenue when it reports  results ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nL8N4081CN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620445852","title":"NRx Pharmaceuticals to host full-year 2025 financial results conference call","url":"https://stock-news.laohu8.com/highlight/detail?id=2620445852","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620445852?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:03","pubTimestamp":1773918198,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals will host a conference call on March 24, 2026 at 8:00am ET to report full-year 2025 financial results.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDLccX6Jt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","BK4007","SG9999014005.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014013.SGD","NRXP","IE00BGHQF748.EUR","BK4585","IE00B3QW5Z07.USD","BK4588","LU2095319765.USD","LU0314104364.USD","IE00BN0W2T93.GBP","BK4112","IE00BKPKM429.USD","IE00BN0W2V16.EUR","NDAQ","SG9999014021.USD","LU2210149790.SGD","IE00BN0W2W23.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620002241","title":"NRX Pharmaceuticals, Inc. (Nasdaq: Nrxp) to Report Full Year 2025 Financial Results and Provide a Corporate Update on March 24, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2620002241","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620002241?lang=en_us&edition=fundamental","pubTime":"2026-03-19 19:00","pubTimestamp":1773918002,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nTUA8GWJS5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620142692","title":"FDA finds no bioequivalence deficiencies in NRX Pharmaceuticals’ preservative-free ketamine ANDA review","url":"https://stock-news.laohu8.com/highlight/detail?id=2620142692","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620142692?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:02","pubTimestamp":1773745378,"startTime":"0","endTime":"0","summary":"NRx said the FDA Office of Generic Drugs’ Bioequivalence Program informed the company in writing that it has not identified any bioequivalence deficiencies at this time for NRx’s preservative-free ketamine ANDA, subject to final supervisory review. NRx continues to expect an FDA GDUFA decision on the ANDA in Summer 2026. The company said its preservative-free ketamine formulation is intended to be free of benzethonium chloride and is expected to demonstrate three years of room-temperature stability and sterility.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL8Jzt9x:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU2210150020.SGD","SG9999014021.USD","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","SG9999014005.SGD","LU0314104364.USD","SG9999014039.USD","IE00BKPKM429.USD","IE00B64PRP62.GBP","BK4007","SG9999014013.SGD","NDAQ","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4588","LU2210149790.SGD","LU2095319765.USD","NRXP","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620426557","title":"NRX Pharmaceuticals (Nasdaq:Nrxp) Announces FDA Bioequivalence Determination by Office of Generic Drugs for NRX’s Preservative-Free Ketamine Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2620426557","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620426557?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:00","pubTimestamp":1773745202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nTUA9BFGLL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620888496","title":"NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2620888496","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620888496?lang=en_us&edition=fundamental","pubTime":"2026-03-17 03:25","pubTimestamp":1773689100,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRXP/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 16, 2026 15:25 ET (19:25 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619679457","title":"NRx Pharmaceuticals confirms path to NDA following Type C meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2619679457","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619679457?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:15","pubTimestamp":1773659708,"startTime":"0","endTime":"0","summary":"NRx Pharmaceuticals (NRXP) has received confirmatory minutes from an in-person Type C guidance meeting at the headquarters of the US Food and Drug ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-confirms-path-to-nda-following-type-c-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nrx-pharmaceuticals-confirms-path-to-nda-following-type-c-meeting-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NRXP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452151","title":"FDA agrees to review NRX-100 NDA using clinical trials and real-world evidence","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452151","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452151?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:02","pubTimestamp":1773658941,"startTime":"0","endTime":"0","summary":"NRx said the FDA provided confirmatory minutes from an in-person Type C meeting supporting a path to a New Drug Application for NRX-100  for depression, including patients with suicidality. The FDA indicated it is willing to review existing adequate and well-controlled trial data along with real-world evidence from Osmind as confirmatory evidence of efficacy. NRx said the FDA did not request additional clinical trials and does not expect additional nonclinical data or bridging studies for the preservative-free formulation. The company said it plans to submit the NRX-100 NDA by June 2026.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDLbmJXxm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00B3QW5Z07.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4112","BK4585","LU2095319765.USD","SG9999014013.SGD","BK4588","NDAQ","LU2210150020.SGD","BK4007","NRXP","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","LU2210149790.SGD","LU0314104364.USD","SG9999014021.USD","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619452916","title":"NRX Pharmaceuticals Inc - to Submit Nda for NRX-100 by June 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619452916","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619452916?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:00","pubTimestamp":1773658803,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUA3HBZNG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRXP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.salbergco.com","stockEarnings":[{"period":"1week","weight":0.0417},{"period":"1month","weight":0.3006},{"period":"3month","weight":-0.0343},{"period":"6month","weight":-0.2902},{"period":"1year","weight":0.3158},{"period":"ytd","weight":-0.1697}],"compareEarnings":[{"period":"1week","weight":0.0317},{"period":"1month","weight":-0.0033},{"period":"3month","weight":-0.0196},{"period":"6month","weight":0.0352},{"period":"1year","weight":0.3616},{"period":"ytd","weight":-0.0087}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.074525},{"month":2,"riseRate":0.2,"avgChangeRate":-0.102766},{"month":3,"riseRate":0.4,"avgChangeRate":-0.034339},{"month":4,"riseRate":0.4,"avgChangeRate":-0.168849},{"month":5,"riseRate":0.75,"avgChangeRate":0.071255},{"month":6,"riseRate":0.4,"avgChangeRate":-0.166652},{"month":7,"riseRate":0.4,"avgChangeRate":0.039708},{"month":8,"riseRate":0.2,"avgChangeRate":-0.14211},{"month":9,"riseRate":0.4,"avgChangeRate":-0.012776},{"month":10,"riseRate":0.6,"avgChangeRate":0.037482},{"month":11,"riseRate":0.4,"avgChangeRate":0.048439},{"month":12,"riseRate":0.6,"avgChangeRate":0.121824}],"exchange":"NASDAQ","name":"NRX Pharmaceuticals Inc.","nameEN":"NRX Pharmaceuticals Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NRX Pharmaceuticals Inc.,NRXP,NRX Pharmaceuticals Inc.股票,NRX Pharmaceuticals Inc.股票老虎,NRX Pharmaceuticals Inc.股票老虎国际,NRX Pharmaceuticals Inc.行情,NRX Pharmaceuticals Inc.股票行情,NRX Pharmaceuticals Inc.股价,NRX Pharmaceuticals Inc.股市,NRX Pharmaceuticals Inc.股票价格,NRX Pharmaceuticals Inc.股票交易,NRX Pharmaceuticals Inc.股票购买,NRX Pharmaceuticals Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NRX Pharmaceuticals Inc.(NRXP),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NRX Pharmaceuticals Inc.(NRXP) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}